Immunome, Inc.

Developing antibody-based therapeutics by unlocking the human memory B cell response.

[Immunome, Inc. @Immunome]

We’re thrilled to announce we have entered a definitive merger agreement with Morphimmune! This merger will unite our technology platforms for the development of best-in-class targeted #cancer therapies across multiple modalities. More here: https://t.co/xLX0SyrYqB $IMNM

[Immunome, Inc. @Immunome]

Immunome Senior Director of Antibody Engineering, Pavel Nikitin, Ph.D., recently facilitated a discussion on mining the antibody repertoire from tumor patients at @hub_xchange’s Antibody Therapeutics Xchange East Coast 2023. Read more here: https://t.co/T2OZf60G6d

[Immunome, Inc. @Immunome]

Immunome’s President and CEO, Purnanand Sarma, Ph.D., & CFO Corleen Roche, were featured in @BioProcessOL where they spoke in detail with @Matt Pillar about Immunome's platform partnership potential & strategic collaboration with AbbVie. More here: https://t.co/cumUNHQkPy $IMNM

[Immunome, Inc. @Immunome]

Immunome's CTO Matt Robinson, Ph.D., was featured in a @Pharmashot Q&A with Senior Editor Smriti Bhardwaj where he discussed Immunome's deal with AbbVie and the potential of our Discover Engine. Read more here: https://t.co/I30hnIXU6v $IMNM

[Immunome, Inc. @Immunome]

Exciting news! Preclinical data on our anti-IL38 program has been published in mAbs under the title "IL-38 blockade induces anti-tumor immunity by abrogating tumor-mediated suppression of early immune activation:" https://t.co/pu4yW8GByV $IMNM

[Immunome, Inc. @Immunome]

Matt Robinson, Ph.D., Immunome's CTO, was recently featured on @Labiotech_eu's Beyond Biotech podcast where he spoke with Jim Cornall in depth about #ADCs and our Discovery Engine platform potential. Listen here: https://t.co/QdapLrGnBB $IMNM

[Immunome, Inc. @Immunome]

#ICYMI: Our CTO Matt Robinson, Ph.D. presented on our Discovery Engine’s ability to utilize human memory #Bcells to identify targets for development as #AntibodyDrugConjugates at the World ADC London conference. Learn more about our research: https://t.co/FHu0vDu25b $IMNM

[Immunome, Inc. @Immunome]

Our CTO Matt Robinson, Ph.D. will join colleagues in #biotech and #pharma in presenting at the 2023 @SAPAGP Conference on Saturday, April 1. Matt will introduce our human #MemoryBCell platform and how it can support #drugdevelopment. More here: https://t.co/TDXPRqHWqK $IMNM

[Immunome, Inc. @Immunome]

Want to learn more about how human memory #Bcells could be used to identify novel targets for development as #ADCs? Today our CTO Matthew Robinson, Ph.D., will present on our Discovery Engine at the 13th Annual @World_ADC London conference. Read more: https://t.co/ImjiF3jRby

[Immunome, Inc. @Immunome]

Want to learn more about how human memory #Bcells could be used to identify novel targets for development as #ADCs? Today our CTO Matthew Robinson, Ph.D., will present on our Discovery Engine at the 13th Annual @World_ADC London conference. Read more: https://t.co/ImjiF3jRby

[Immunome, Inc. @Immunome]

We’re delighted to be partnering with the World ADC London Summit from March 13-16, Europe’s definitive #AntibodyDrugConjugate event dedicated to maximizing the therapeutic window of ADCs. Register & use our code (30318SPN) to receive a 20% discount: https://t.co/IdfpiRvWNs

[Immunome, Inc. @Immunome]

Our CTO Matthew Robinson, Ph.D., will discuss how our Discovery Engine can harness the power of human memory #Bcells to identify novel targets for development as #AntibodyDrugConjugates at the 13th Annual @World_ADC London conference. Read more: https://t.co/ImjiF3kp16

[Immunome, Inc. @Immunome]

We are pleased to announce the formation of our Antibody-Drug Conjugate (ADC) & T cell redirection (TCR) advisory board comprised of Drs. John Lambert and Anthony Tolcher, to prioritize selection of novel targets for ADC & TCR modalities. More here: https://t.co/DRaS0xMMQl $IMNM

[Immunome, Inc. @Immunome]

We are proud to collaborate with @abbvie and look forward to utilizing our Discovery Engine to discover novel #cancer therapeutics by harnessing the power of human memory #Bcells. To learn more, visit @endpts: https://t.co/kwzpJFDOgU

[Immunome, Inc. @Immunome]

We’re excited to announce our multi-year collaboration with @abbvie! Our collaboration will utilize our proprietary Discovery Engine to unlock novel #cancer biology & identify up to 10 antibody-target pairs arising from 3 specified tumor types. More here: https://t.co/ZuOIGGchB7

[Immunome, Inc. @Immunome]

We look forward to presenting results at #SITC22. Our poster is focused on IMM20059, an #antibody that binds epsin-1 (EPN1), a novel target in the membrane dynamics/exosome target class which inhibits tumor growth. Press release here: https://t.co/Cr7k36AXzT #Exosome101

[Immunome, Inc. @Immunome]

Immunome’s discovery engine suggests that the human immune system is responding against cellular processes regulating membrane dynamics and #exosome formation. We look forward to understanding how targeting this process may lead to therapeutic benefit.
#Exosome101

[Immunome, Inc. @Immunome]

Immunome’s discovery engine interrogates human memory #BCells to see how #cancer cells look in the context of the #TumorMicroenvironment to identify #antibody-based treatments. See more on our website: https://t.co/VztmCouBly #Exosome101

[Immunome, Inc. @Immunome]

#Exosomes do not just modify cancer cells and the #TumorMicroenvironment by releasing their contents: they also have PD-L1, an immune checkpoint protein, on their surface. #PDL1 inhibits anti-tumor immune responses. Read more in @Nature: https://t.co/b1FMPAz5ET #Exosome101

[Immunome, Inc. @Immunome]

Knowledge of #exosomes has blossomed in the 21st century, with research linking exosomes to cancer growth & #metastasis. Exosomes condition the #TumorMicroenvironment or “fertilize the soil” to enable cancer growth. More in @NatureRevCancer: https://t.co/Bg6vJ9LfBn #Exosome101